This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Putting a Value on Provenge

Disease Prevalence

Now, with many diseases, including most cancers, you can also look at disease prevalence, which is the total number of patients at any one time. Prevalence numbers will be larger than incidence numbers because it takes into account more than one year.

For the purposes of my model, I found finding prevalence figures for prostate cancer difficult, so I chose to use incidence. That's me being conservative, a stance I'll take throughout this model because I'd rather underestimate than overestimate.

Provenge, at least initially, will not be given to all prostate cancer patients. Instead, use will be restricted to patients who have metastatic, androgen-independent (hormone-refractory) disease, which means their cancer has spread beyond the prostate and it is no longer being controlled by hormone treatments. These patients will also be asymptomatic, which means they won't have any outward symptoms, such as bone pain, which could signal new growth of their cancer.

Here comes the hard part -- figuring out the percentage of prostate cancer patients who fit that category, which is labeled "AIPrC" in my model above. After a lot of Googling and research, including looking back at some old analyst notes, my best guess is that 35% of prostate cancer patients are no longer responding to hormone treatments. That's what I used in my revenue model to come up with a total population of AIPrC patients -- the target group for Provenge.

Not all eligible prostate cancer patients will choose to take Provenge. How many will? Frankly, this is an educated guess, especially since Provenge is a first-in-class cancer immunotherapy without precedent.

But again, after some research, I learned that about 65% of hormone-refractory prostate cancer patients choose to move onto chemotherapy treatment for their disease. Provenge, if approved, would slot between hormone therapy and chemotherapy, so for my modeling purposes, I decided to assume that the same 65% of patients would choose Provenge. Given the excellent side-effect profile of Provenge, this percentage might actually end up higher, but again, I like to be conservative.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs